Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

Carlos Vallejo,1 Montserrat Batlle,2 Lourdes Vázquez,3 Carlos Solano,4 Antonia Sampol,5 Rafael Duarte,6 Dolores Hernández,7 Javier López,8 Montserrat Rovira,9 Santiago Jiménez,10 David Valcárcel,11 Vicente Belloch,12 Mónica Jiménez,13 and Isidro Jarque;14 on behalf of the Subcommittee of Non-Infectious Complications of the Grupo Español de Trasplante Hematopoyético (GETH)

1Hospital Universitario Central de Asturias, Oviedo; 2Hospital Universitari Germans Trias i Pujol, Badalona; 3Hospital Universitario de Salamanca, Salamanca; 4Hospital Clínico Universitario-INCLIVA, Valencia; 5Hospital Son Dureta, Palma de Mallorca; 6Catalan Institute of Oncology-Idibell, L'Hospitalet de Llobregat; 7Hospital Universitario La Paz, Madrid; 8Hospital Ramón y Cajal, Madrid; 9Hospital Clínico Provincial de Barcelona, Barcelona; 10Hospital Dr. Negrín, Las Palmas de Gran Canaria; 11Hospital de la Santa Creu i Sant Pau, Barcelona; 12ERSA, Valencia; 13Novartis Farmacéutica S.A., Barcelona; 14Hospital Universitario La Fe, Valencia, Spain

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014.105908
Manuscript received on February 25, 2014. Manuscript accepted on July 2, 2014.
Correspondence: carlosvallejo@me.com
Supplemental Information and Tables

Supplemental Information

Inclusion Criteria

>18 years old

Allogeneic HSCT at least 6 months prior to enrollment

Transfusional iron overload

Serum ferritin >1000 ng/mL or

>20 units red blood cell transfusions

Absolute neutrophil count >1000/mm$^3$

Exclusions Criteria

Iron overload not related to transfusion

Uncontrolled hypertension

Active viral hepatitis

Human immunodeficiency virus infection

Serum creatinine >2x ULN or creatinine clearance <50 mL/min

Urine protein/creatinine ratio >0.5 mg/mL in 2 samples (separated by > 1 week)

Aspartate aminotransferase >5x ULN

Active concomitant malignancy

Prior use of iron chelators after HSCT

History of ocular toxicity related to iron chelation

Treatment with investigational systemic drugs within ≤ 4 weeks or investigational topical drugs within the previous 7 days

Systemic or psychiatric disease which may preclude the patient from carrying out the
investigational treatment

Surgical or medical history which may impact absorption, distribution, metabolism or excretion of any drug

History of non-compliance

Drug or alcohol abuse within the prior 12 months

Pregnant or nursing women or adults of child-bearing potential not using effective methods of contraception

HSCT: hematopoietic stem cell transplant; ULN: upper limit of normal
## Study Visit Schedule

<table>
<thead>
<tr>
<th>Week</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>16</th>
<th>20</th>
<th>24</th>
<th>28</th>
<th>32</th>
<th>36</th>
<th>40</th>
<th>44</th>
<th>48</th>
<th>52</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical examination</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Relevant clinical history / Current medical condition / Pregnancy test / Height</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye examination and audiometry</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology and biochemistry</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Transfusion</td>
<td>As necessary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iron metabolism</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Serum creatinine and creatinine clearance</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MRI</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Proteinuria</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse events</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>GVHD / Infections / SOS</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

1. Serum ferritin, transferrin, transferrin saturation
2. MRI: Magnetic Resonance Imaging, at selected sites
3. SOS: sinusoidal obstruction syndrome
Supplemental Figure 1 Patient Disposition

Patients included (n=30)

Reasons for discontinuation (n=8)
- Consent withdrawn (n=1)
- Disease progression (n=3)
- Death (n=2)
- Adverse events (n=1)*
- Unsatisfactory therapeutic effect (n=1)
*creatinine increase drug-related

Patients completed (n=22)
- Achieving SF ≤400 ng/mL before 52 weeks of treatment (n=8)
- After 52 weeks of treatment (n=14)